

Application Number: 10/821,382

(e) lower alkylamino lower alkyl unsubstituted, mono or disubstituted amino;
lower alkylamino lower alkyl morpholinyl, lower alkylamino lower alkyl pyrrolidinyl,
lower alkylamino lower alkyl piperidinyl, lower alkylamino lower alkyl piperazinyl,
-or a pharmaceutically acceptable salt thereof.

7. (previous amendments applied, currently amended) A compound of Formula (I)
according to claim 1, wherein

X is oxygen,

Y is a direct bond,


Z is phenyl,

R₁ is: 3-pyridyl or 4-pyridyl


R₂ is: methyl, F, Cl or hydrogen,

R₃ is hydrogen,

R₄ is:




Application Number: 10/821,382

 R_4 is (cont'd) :

Application Number: 10/821,382

R₄ is (cont'd) :



Application Number: 10/821,382

R is hydrogen, lower alkyl, aliphatic, or cycloaliphatic-radicals,
or a pharmaceutically acceptable salt thereof.

8. (previous amendments applied, currently amended) A compound of Formula (I) according to claim 1 is selected from:

[4-(2-aminoethoxy)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

[4-(fluoropiperazinylmethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}-4-[(1-methylpyrrolidin-2-yl)methoxy]phenyl}carboxamide

~~N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}-4-(pyrrolidin-3-ylamino)phenyl}carboxamide~~

[4-(aminofluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

~~N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}-4-(methylpyrrolidin-3-ylamino)phenyl}carboxamide~~

{4-[fluoro(4-methylpiperazinyl)methyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

[4-(aminodifluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

(4-{fluoro[(1-methylpyrrolidin-3-yl)amino]methyl}phenyl)-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

{4-[fluoro(methylpyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

[4-({[2-(dimethylamino)ethyl]amino}fluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

[4-(difluoropiperazinylmethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

{4-[difluoro(4-methylpiperazinyl)methyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide

Application Number: 10/821,382

[4-({[2-(dimethylamino)ethyl]amino}difluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
(4-{fluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl}-phenyl)-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[fluoro(pyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[(4-ethylpiperazinyl)difluoromethyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[(4-ethylpiperazinyl)fluoromethyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
(4-{difluoro[methyl(1-methylpyrrolidin-3-yl)amino]methyl}-phenyl)-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[difluoro(methylpyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
[4-({[2-(dimethylamino)ethyl]amino}fluoromethyl)phenyl]-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
{4-[difluoro(pyrrolidin-3-ylamino)methyl]phenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide
~~(4-{[methyl(1-methylpyrrolidin-3-yl)amino]methyl}phenyl)-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide~~
~~{4-(methylpyrrolidin-3-ylamino)methylphenyl}-N-{4-methyl-3-[(4-(3-pyridyl)pyrimidin-2-yl)amino]phenyl}carboxamide~~


or a pharmaceutically acceptable salt thereof.

9. (original) A pharmaceutical acceptable salt according to any one of claims 1 to 8 is methanesulfonic acid salt.

Application Number: 10/821,382

Remarks

The examiner raised new issues under 35 U.S.C. §112, second paragraph, claim 7 contains the following fragments of R_4 , which lack antecedent basis in claim 1.



As can be seen from present above amendments to the claim 7, these fragments of R_4 have been canceled. Furthermore, four examples fall within this genus have been canceled as well. Therefore, these grounds of advisory have been adopted and these new issues have been obviated.

The examiner raised new issues under 35 U.S.C. §103 to require further consideration, suggested that the term "lower alkyl oxyheterocyclyl" falls within the reference genus of WO 04/99186. As can be seen from the present above amendments, "lower alkyl oxyheterocyclyl" as well as its fragments in claim 7 has been canceled. Therefore, these grounds of advisory have been adopted and these new issues have been obviated.

CONCLUSION

In light of the foregoing amendments and remarks, it is believed that the application is condition for allowance, so that a prompt and favorable response is earnestly solicited.

Respectfully submitted,
GUOQING PAUL CHEN
Tel: 626-482-9676
Dated: February 8, 2007